NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has agreed to a renegotiated contract with Marijn Dekkers that gives the CEO a base salary of $1.17 million per year as well as a target incentive bonus of 125 percent of base salary, the company disclosed in a filing this week with the US Securities and Exchange Commission. The new contract holds through the end of 2017.
If the company opts to sack Dekkers before the contract ends, it will owe him a buyout of three times his current base salary, three times his target bonus, a pro-rata bonus for the year of the termination, and outplacement services worth up to $50,000.
Dekkers base salary in 2007 was $1.13 million, up from $1.04 million in 2006. He also received a 2007 bonus of $1.9 million.
NuGen Technologies has brought Douglas Amorese aboard to step into the new post of VP of research and development. Amorese will work with other senior executives to develop the company’s life science IP portfolio.
He formerly was responsible for product development projects in Agilent Technologies’ genomics program, and before that he worked at DuPont and at Life Technologies. Amorese also was a post-doctoral fellow at the Salk Institute and at the University of Texas Health Science Center.
Scott Strobel, professor of molecular biophysics and biochemistry at Yale University, has been named winner of the Schering-Plough Research Institute Award. Strobel has focused on RNA research at Yale over the past dozen years, and he previously worked in a post-doctorate capacity in Thomas Cech’s lab at the University of Colorado.
Asterand has appointed Peter Coggins to be a non-executive director. Coggins formerly was president of PerkinElmer Life and Analytical Sciences, and he was executive VP of global sales at Amersham Biosciences. Coggins also was a chairman of the Analytical & Life Science Sciences Association and he is now a director on the boards of DeltaDot and Biohit Oyj.
US Food and Drug Administration Commissioner Andrew von Eschenbach has tapped Frank Torti to be the FDA’s principal deputy commissioner and its first chief scientist, a newly created position. Both a clinician and a researcher in molecular oncology, Torti is currently a professor of medicine, chair of the Department of Cancer Biology, and director of the Comprehensive Cancer Center at Wake Forest University School of Medicine.
Torti also is a member of the National Institutes of Health's National Advisory Council for Complementary and Alternative Medicine and he founded and currently serves as president of the Cancer Biology Training Consortium.
Francis Collins has received the Inamori Ethics Prize from the Inamori International Center for Ethics and Excellence at Case Western Reserve University. Collins is director of the National Human Genome Research Institute. The Inamori prize includes a $25,000 award that is intended to support the recipient’s ongoing research.
Collins has "consistently emphasized the importance of ethical and legal issues in genetics, while at the same time working tirelessly to improving the lives of people worldwide," said Inamori Center Director Gregory Eastwood.
Response Genetics has appointed John Ferrara to its board of directors. Ferrara is currently chief financial officer at EDGAR Online, and he formerly was interim CFO at GAMCO Investors and president of the LGL Group. He also has held CFO posts at Space Holding Corporation, Golden Books Family Entertainment, and Renaissance Communications.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.